Blome, Sandra

Nielsen, Jens

Rangelova, Desislava Yordanova

Strandbygaard, Bertel

Uttenthal, Åse

Outbreaks of Classical Swine Fever (CSF) in the European Union have caused enormous economical losses. To facilitate the possibility of free trade with pigs and their products, a chimeric live DIVA vaccine CP7_E2alf was developed. Most likely, passive immunity against CSF virus in populations previously vaccinated with C-strain interferes with the efficacy of CP7_E2alf vaccination. To study the interaction with maternal antibodies, the efficacy of CP7_E2alf in piglets from C-strain vaccinated sows was examined. At 5 or at 8 weeks of age, piglets were vaccinated with CP7_E2alf. The vaccinated piglets together with mock-vaccinated littermate controls were challenged 2 weeks post vaccination with highly virulent CSFV Kozlov. The results showed that CP7_E2alf is effective in preventing mortality, severe clinical signs and pathological lesions in piglets vaccinated at 5 or at 8 weeks of age. Interestingly, the antibodies in the mock-vaccinated control piglets partly neutralized the challenge virus. In earlier studies CSFV Koslov has resulted in 100% mortality in naïve piglets, in this study mortality was reduced to 30% in the piglets infected at 7 weeks of age and to 50% in the piglets infected at 10 weeks of age. In the present study optimal time point for vaccination of piglets with passive immunity was found to be 5 weeks of age

Online Research Database In Technology

                       General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.  • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal   If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.     Downloaded from orbit.dtu.dk on: Dec 20, 2017The efficacy of CP7_E2alf: an animal study involving piglets from C–strain vaccinatedsowsRangelova, Desislava Yordanova; Nielsen, Jens; Strandbygaard, Bertel; Blome, Sandra; Uttenthal, ÅsePublication date:2012Document VersionPublisher's PDF, also known as Version of recordLink back to DTU OrbitCitation (APA):Rangelova, D. Y., Nielsen, J., Strandbygaard, B., Blome, S., & Uttenthal, Å. (2012). The efficacy of CP7_E2alf:an animal study involving piglets from C–strain vaccinated sows. Abstract from Annual Meeting of the NationalReference Laboratories of CSF, Hannover, Germany.The efficacy of CP7_E2alf: an animal study involving piglets from C–strain vaccinated sows Desislava Rangelovaa, Jens Nielsena, Bertel Strandbygaarda, Sandra Blomeb, Åse Uttenthala aTechnical University of Denmark, National Veterinary Institute, Lindholm, DK-4771Kalvehave, Denmark bFriedrich-Loeffler-Institute, Institute of Diagnostic Virology, Suedufer 10, 17493 Greifswald-Insel Riems, Germany  Outbreaks of Classical Swine Fever (CSF) in the European Union have caused enormous economical losses. To facilitate the possibility of free trade with pigs and their products, a chimeric live DIVA vaccine CP7_E2alf was developed. Most likely, passive immunity against CSF virus in populations previously vaccinated with C-strain interferes with the efficacy of CP7_E2alf vaccination. To study the interaction with maternal antibodies, the efficacy of CP7_E2alf in piglets from C-strain vaccinated sows was examined. At 5 or at 8 weeks of age, piglets were vaccinated with CP7_E2alf. The vaccinated piglets together with mock-vaccinated littermate controls were challenged 2 weeks post vaccination with highly virulent CSFV Kozlov. The results showed that CP7_E2alf is effective in preventing mortality, severe clinical signs and pathological lesions in piglets vaccinated at 5 or at 8 weeks of age. Interestingly, the antibodies in the mock-vaccinated control piglets partly neutralized the challenge virus. In earlier studies CSFV Koslov has resulted in 100% mortality in naïve piglets, in this study mortality was reduced to 30% in the piglets infected at 7 weeks of age and to 50% in the piglets infected at 10 weeks of age. In the present study optimal time point for vaccination of piglets with passive immunity was found to be 5 weeks of age.  Acknowledgement: This study is funded from the European Community's Seventh Framework (FP7/2007-2013) under grant agreement n°227003 CP-FP (CSFV_goDIVA).  

The efficacy of CP7_E2alf: an animal study involving piglets from C–strain vaccinated sows

http://orbit.dtu.dk/ws/files/10189994/prod21343912758219.ASUT_efficacy_of_CP7_NSFL_abstract.pdf

The efficacy of CP7_E2alf: an animal study involving piglets from C–strain vaccinated sows

Abstract

Similar works

Full text

Available Versions

Online Research Database In Technology